Form 4: ProMIS Neurosciences CDO Receives Stock Option Grant

Chief Development Officer Johanne Kaplan was granted 50,000 stock options in ProMIS Neurosciences.

Summary

• Johanne Kaplan, Chief Development Officer of ProMIS Neurosciences, was granted 50,000 stock options.
• The options have an exercise price of $10.77 per share.
• The grant date for the options is May 20, 2026.
• The options are set to expire on May 20, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.
• Retention mechanism established via a four-year vesting schedule.

Negatives

• Potential for future shareholder dilution upon the exercise of these options.

Risks

• Vesting is contingent upon continued service to the issuer, creating key-person dependency risk.

Future Outlook

The options vest ratably over a four-year period, contingent upon the reporting person's continued service to the company.

Management Comments

• The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice to incentivize long-term development milestones and executive retention.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard corporate governance practices for executive equity compensation in the biotech industry.

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised in the future.

Next Steps

• Vesting of options over the next four years.

Key Dates

Keywords

ProMIS Neurosciences, PMN, Insider Trading, Stock Options, Executive Compensation, Form 4